Company Overview and News

0
Ashok Leyland Limited - Shareholders meeting

2h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500477 AKLS AKLD ASHOKLEY

0
An evening walk down Dalal Street | Sensex up almost 200 pts, Nifty back at 11,000

5h moneycontrol
After starting the week on a negative note, the market on Tuesday looked to reclaim its positive momentum from last week, backed by sharp gains in midcaps. The Sensex managed to end the day almost 200 points higher, while the Nifty managed to end above 11,000-mark.
IOC 500469 532617 TCHQY HINDUNILVR FEDA 532755 532187 532461 FEDS 500696 500477 FEDERALBNK ASHOKLEY SBAZ INDIGO INDUSINDBK JETAIRWAYS FDBAY 530965 AKLD TECHM 539448 PNJZY PNB AKLS

4
Eicher Motors to make low cost AC buses, open plants outside India

5h moneycontrol
VE Commercial Vehicles (VECV), the joint venture company of Sweden’s Volvo and Delhi-based Eicher Motors, is working on a series of projects including development of low-cost AC buses, electric mobility solutions and setting up of assembly plants outside India.
505200 ECQRY 500477 500570 AKLS TATAMOTORS EICHERMOT AKLD TTM ASHOKLEY

0
Ashok Leyland Q1 profit jumps over 3-fold to Rs 370.1 crore

7h livemint
New Delhi: Hinduja flagship firm Ashok Leyland on Tuesday reported over three-fold jump in standalone net profit at Rs370.1 crore in the first quarter ended on 30 June, riding on robust sales.
500477 AKLS AKLD ASHOKLEY

0
Ashok Leyland shares gain 6% after better-than-expected earnings growth in Q1

7h moneycontrol
Commercial vehicle maker Ashok Leyland share price rallied more than 6 percent intraday Tuesday after reporting better-than-expected earnings for the quarter ended June. In actual the stock also rebounded after a 5 percent correction seen in the previous session due to likely increase in load carrying capacity of trucks.
500477 AKLS AKLD ASHOKLEY

0
Ashok Leyland Limited - Financial Result Updates

8h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500477 AKLS AKLD ASHOKLEY

0
Ashok Leyland Q1 profit surges 232% YoY to Rs 370 crore, beats estimates

9h moneycontrol
India’s third largest commercial vehicle maker Ashok Leyland on Tuesday beat analyst expectations with a 232 percent rise in net profit for the June quarter, led by a sustained growth in domestic demand helped by strong uptick in infrastructure activity.
500477 AKLS AKLD ASHOKLEY

0
Ashok Leyland gains over 2% ahead of June quarter results

12h moneycontrol
Shares of Ashok Leyland were trading over 2 percent higher in the morning trade on Tuesday ahead of its June quarter earnings announcement.
500477 AKLS AKLD ASHOKLEY

4
Disabled-friendly transport: Delhi High Court disapproves of AAP government’s approach

2018-07-16 freepressjournal.in
New Delhi: The Delhi High Court today castigated the AAP government for its “blinkered” approach towards ensuring disabled friendly public transportation in the national capital, saying procurement of low floor buses will not help if bus stops are inaccessible.
500477 500570 AKLS TATAMOTORS AKLD TTM ASHOKLEY

0
Ashok Leyland, ICICI Lombard results

2018-07-16 thehindubusinessline
Nearly two dozen companies, including 8K Miles Software Services, Ashok Leyland, Atishay, Crisil, Federal Bank, Goa Carbon, Hindustan Media Ventures, ICICI Lombard General Insurance, Integrated Capital, Jindal Stainless, Indian Metals & Ferro Alloys, Muthoot Capital Services, Nucleus Software Exports, Rallis India, Sintex Industries, Tata Sponge Iron and Zee Entertainment Enterprises will declare their April-June quarter results on Tuesday.
RALLIS GOACARBON 500469 IDBI 531209 MUTHTFN FEDA TATASPONGE FEDS 500355 JSL 500477 ZEEL FEDERALBNK 509567 ASHOKLEY 513010 500116 IBN 532508 FDBAY FERROALL AKLD 533217 511766 ICICIBANK ZEEEY 532174 SINTEX 502742 505537 500141 AKLS NUCLEUS HMVL

5
Ashok Leyland, Tata Motors slip 4-7% after reports of likely hike in truck, tractor trailer load capacity

2018-07-16 moneycontrol
Commerical vehicle makers Ashok Leyland and Tata Motors dropped 6.8 percent and 4 percent respectively after reports of likely increase in load carrying capacity of trucks and tractor trailers.
500477 500570 AKLS TATAMOTORS AKLD TTM ASHOKLEY

4
Ashok Leyland Q1 preview: Analysts see net profit rising threefold on surge in demand

2018-07-16 moneycontrol
Gaining from a continued surge in demand across categories, and last year's lower base, domestic commercial vehicle manufacturer Ashok Leyland will likely post a threefold rise in its bottom line for the June quarter.
500477 500570 AKLS TATAMOTORS AKLD TTM ASHOKLEY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

11h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...